NCT01376388 - Long-term Safety Study for GSK573719/GW642444 in Japanese | Biotech Hunter

Enrollment

131

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK573719/GW642444 Inhalation Powder

GSK573719/GW642444 inhalation powder inhaled orally once daily for 52 weeks.

Trial Locations (23)

802-0083

GSK Investigational Site, Fukuoka

371-0048

GSK Investigational Site, Gunma

732-0052

GSK Investigational Site, Hiroshima

732-0057

GSK Investigational Site, Hiroshima

064-0915

GSK Investigational Site, Hokkaido

080-0805

GSK Investigational Site, Hokkaido

665-0827

GSK Investigational Site, Hyōgo

670-0849

GSK Investigational Site, Hyōgo

300-0053

GSK Investigational Site, Ibaraki

763-8502

GSK Investigational Site, Kagawa

239-0821

GSK Investigational Site, Kanagawa

615-8087

GSK Investigational Site, Kyoto

576-0016

GSK Investigational Site, Osaka

589-0022

GSK Investigational Site, Osaka

590-0064

GSK Investigational Site, Osaka

870-0921

GSK Investigational Site, Ōita

876-0047

GSK Investigational Site, Ōita

436-0022

GSK Investigational Site, Shizuoka

105-0004

GSK Investigational Site, Tokyo

185-0014

GSK Investigational Site, Tokyo

187-0024

GSK Investigational Site, Tokyo

641-8510

GSK Investigational Site, Wakayama

400-0031

GSK Investigational Site, Yamanashi